Abstract
Introduction: No meta-analysis has evaluated azapirones (serotonin 1A receptor partial agonists) as anxiolytics for attention deficit hyperactivity disorder (ADHD). Methods: Randomized controlled trials (RCTs) and single-arm trials published before October 27, 2015 were retrieved from major healthcare databases and clinical trial registries. Relative risk and 95% confidence intervals were calculated. Results: 5 RCTs (n=429) and 3 single-arm studies (n=70) were identified. 3 RCTs compared buspirone vs. methylphenidate in children/adolescents, one buspirone patches vs. placebo patches in children/adolescents, and one atomoxetine plus buspirone vs. atomoxetine vs. placebo in adults. The single-arm studies were buspirone trails in children/adolescents. All-cause discontinuation rates and adverse events did not differ between pooled buspirone and methylphenidate groups. No other meta-analyses of buspirone efficacy and safety vs. comparators were conducted due to insufficient data. 2 RCTs found no significant differences in parent and teacher ADHD-Rating Scale total scores between buspirone and methylphenidate, while one reported that methylphenidate improved parent and teacher ADHD-RS total scores vs. buspirone. Discussion: It remains unclear whether buspirone use has benefit for ADHD patients and therefore further evidence is needed for better clinical use of buspirone in patients with ADHD.
| Original language | English |
|---|---|
| Pages (from-to) | 97-106 |
| Number of pages | 10 |
| Journal | Pharmacopsychiatry |
| Volume | 49 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 01-05-2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Psychiatry and Mental health
- Pharmacology (medical)
Cite this
}
Azapirones for Attention Deficit Hyperactivity Disorder : A Systematic Review. / Matsui, Y.; Matsunaga, S.; Matsuda, Y.; Kishi, T.; Iwata, Nakao.
In: Pharmacopsychiatry, Vol. 49, No. 3, 01.05.2016, p. 97-106.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Azapirones for Attention Deficit Hyperactivity Disorder
T2 - A Systematic Review
AU - Matsui, Y.
AU - Matsunaga, S.
AU - Matsuda, Y.
AU - Kishi, T.
AU - Iwata, Nakao
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Introduction: No meta-analysis has evaluated azapirones (serotonin 1A receptor partial agonists) as anxiolytics for attention deficit hyperactivity disorder (ADHD). Methods: Randomized controlled trials (RCTs) and single-arm trials published before October 27, 2015 were retrieved from major healthcare databases and clinical trial registries. Relative risk and 95% confidence intervals were calculated. Results: 5 RCTs (n=429) and 3 single-arm studies (n=70) were identified. 3 RCTs compared buspirone vs. methylphenidate in children/adolescents, one buspirone patches vs. placebo patches in children/adolescents, and one atomoxetine plus buspirone vs. atomoxetine vs. placebo in adults. The single-arm studies were buspirone trails in children/adolescents. All-cause discontinuation rates and adverse events did not differ between pooled buspirone and methylphenidate groups. No other meta-analyses of buspirone efficacy and safety vs. comparators were conducted due to insufficient data. 2 RCTs found no significant differences in parent and teacher ADHD-Rating Scale total scores between buspirone and methylphenidate, while one reported that methylphenidate improved parent and teacher ADHD-RS total scores vs. buspirone. Discussion: It remains unclear whether buspirone use has benefit for ADHD patients and therefore further evidence is needed for better clinical use of buspirone in patients with ADHD.
AB - Introduction: No meta-analysis has evaluated azapirones (serotonin 1A receptor partial agonists) as anxiolytics for attention deficit hyperactivity disorder (ADHD). Methods: Randomized controlled trials (RCTs) and single-arm trials published before October 27, 2015 were retrieved from major healthcare databases and clinical trial registries. Relative risk and 95% confidence intervals were calculated. Results: 5 RCTs (n=429) and 3 single-arm studies (n=70) were identified. 3 RCTs compared buspirone vs. methylphenidate in children/adolescents, one buspirone patches vs. placebo patches in children/adolescents, and one atomoxetine plus buspirone vs. atomoxetine vs. placebo in adults. The single-arm studies were buspirone trails in children/adolescents. All-cause discontinuation rates and adverse events did not differ between pooled buspirone and methylphenidate groups. No other meta-analyses of buspirone efficacy and safety vs. comparators were conducted due to insufficient data. 2 RCTs found no significant differences in parent and teacher ADHD-Rating Scale total scores between buspirone and methylphenidate, while one reported that methylphenidate improved parent and teacher ADHD-RS total scores vs. buspirone. Discussion: It remains unclear whether buspirone use has benefit for ADHD patients and therefore further evidence is needed for better clinical use of buspirone in patients with ADHD.
UR - http://www.scopus.com/inward/record.url?scp=84974625940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84974625940&partnerID=8YFLogxK
U2 - 10.1055/s-0042-102457
DO - 10.1055/s-0042-102457
M3 - Review article
VL - 49
SP - 97
EP - 106
JO - Pharmacopsychiatry
JF - Pharmacopsychiatry
SN - 0176-3679
IS - 3
ER -